Back Back

2021 American Society of Hematology Annual Meeting *

December 11-14, 2021; Atlanta, Georgia
Review slidesets and expert analyses of key studies from the 2021 Hematology Annual Meeting!

Share

Program Content

Activities

Key Studies From ASH 2021
An Expert’s Guide to ASH 2021: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2021

Expires: December 07, 2022

17 Capsule Summary Slidesets

Activities

Mosunetuzumab in R/R FL
Mosunetuzumab, a CD20 x CD3 Bispecific Antibody, in R/R Follicular Lymphoma With ≥2 Previous Therapies: Pivotal Phase II Trial Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

View Activity
ELARA High-Risk RR FL
Phase II ELARA: Extended Follow-up and Subgroup Analysis of Tisagenlecleucel in High-Risk R/R Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

View Activity
ZUMA-7
Primary Analysis of ZUMA-7: Randomized Phase III Trial of 2L Axicabtagene Ciloleucel vs Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

View Activity
Valemetostat for R/R ATL
Pivotal Phase II Trial of Valemetostat, an EZH1/EZH2 Inhibitor, in Patients With R/R Adult T-Cell Leukemia/Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
ELEVATE-RR AEs
ELEVATE-RR: Characterization of BTKi-Related AEs in Acalabrutinib vs Ibrutinib in Previously Treated CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

View Activity
CITADEL-205: Parsaclisib in R/R MCL
CITADEL-205: Phase II Study of Parsaclisib in Patients With BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
MK-1026 in CLL/SLL
Phase II Study of Novel BTK Inhibitor MK-1026 in Patients With R/R CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity
ASCEND 3-Yr Update
3-Yr Follow-up of ASCEND Phase III Trial: Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab in R/R CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
SEQUOIA: zanubrutinib in CLL/SLL
Phase III SEQUOIA Trial of Zanubrutinib vs Bendamustine and Rituximab in Previously Untreated CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

View Activity
MRD Surveillance in DLBCL
Prospective Study Evaluating MRD and CT Imaging Surveillance Following First-line Treatment in Patients With DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
Alliance 051701
Alliance 051701: Randomized Phase II/III Trial of DA-EPOCH-R ± Venetoclax in Patients With Previously Untreated Double-Hit Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
CAPTIVATE MRD Cohort 2-Yr Update
CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity
GLOW: Ibr + Ven and MRD
GLOW: MRD Outcomes After First-line Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Older/Unfit Patients With CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2021

Expires: December 11, 2022

View Activity
Parsaclisib in R/R FL
CITADEL-203 Phase II Study of the PI3Kδ Inhibitor Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
TRANSFORM: Liso-Cel in LBCL
TRANSFORM: Lisocabtagene Maraleucel vs Salvage Chemotherapy Followed by ASCT as Second-Line Treatment in Relapsed/Refractory Large B-Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity
POLARIX: Polatuzumab vedotin
POLARIX Trial of Polatuzumab Vedotin + R-CHP VS R-CHOP in Patients With Previously Untreated DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
BELINDA: Tisagenlecleucel in R/R NHL
Phase III BELINDA Trial of Tisagenlecleucel vs Standard of Care as Second-line Treatment for R/R Aggressive B-Cell Non-Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity

Activities

Lymphoma/CLL Highlights: ASH 2021
Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2021
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 10, 2022

Expires: May 09, 2023

11 Capsule Summary Slidesets

Activities

Pelabresib in MF
MANIFEST: Pelabresib (CPI-0610) Monotherapy in Patients With Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
Venetoclax/Azacitidine in MDS
Phase Ib Study: Venetoclax/Azacitidine in Treatment-Naive Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

View Activity
PANTHER
PANTHER: Randomized Phase III Trial of First-line Pevonedistat + Azacitidine vs Azacitidine in Higher-Risk MDS/CMML or AML With 20% to 30% Marrow Blasts
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

View Activity
CPX-351 in HR MDS
Phase II Trial of CPX-351 as First-line Treatment in Patients With Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
Sabatolimab + HMA in MDS/AML
Phase Ib Study of Sabatolimab + Hypomethylating Agents for Very High–Risk/High-Risk MDS and Newly Diagnosed AML: Final Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
FIGHT-203: Pemigatinib in MLN<sup><i>FGR1</i></sup>
FIGHT-203: Phase II Trial of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
Rusfertide in PV
Phase II Trial of Rusfertide (PTG-300) in Patients With Phlebotomy-Dependent Polycythemia Vera
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
HMA + Ven in MDS
Retrospective Analysis of Venetoclax + Hypomethylating Agents for Patients With Higher-Risk Myelodysplastic Syndromes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
CPX-351 in Higher-Risk MDS
Pilot Study of CPX-351 in Transplant-Eligible Patients With Previously Untreated Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
IPSS-M Development
Development and Validation of a Molecular International Prognostic Scoring System (IPSS-M) for MDS Risk Stratification
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

View Activity
MDS: LEN ± ELT
Phase II Trial of Lenalidomide and Eltrombopag for Low-Risk/Intermediate-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
View Activity

Activities

Hematology 2021: MDS/MPN
Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Independent Conference Coverage of the 2021 ASH Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2022

Expires: May 10, 2023

15 Capsule Summary Slidesets

Activities

Cevostamab in RRMM
Phase I Study of Cevostamab in Patients With Heavily Pretreated R/R MM: Dosing Schedule, Updated Safety and Efficacy Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
MonumenTAL-1: Talquetamab in R/R MM
Phase I MonumenTAL-1: GPCR5D x CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

View Activity
REGN5458 in R/R MM
Phase I/II Study of BCMA x CD3 Bispecific Antibody REGN5458 in R/R MM: Updated Safety and Efficacy Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
IBER + DEX in RRMM
Dose-Expansion Results From Phase Ib/IIa CC-220-MM-001 Trial: Iberdomide + Dexamethasone in Relapsed/Refractory MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2021

Expires: December 11, 2022

View Activity
Belantamab + Len/Dex in NDMM
Phase I/II Study: Belantamab Mafodotin With Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
DREAMM-9
Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
GMMG-HD7
GMMG-HD7: Phase III Trial of Isatuximab + VRd vs VRD Alone as Induction Therapy for Newly Diagnosed, ASCT-Eligible Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
GEM2014MAIN: Ixa + LenDex
Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
CARTITUDE-1: 2-Yr Update
CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel in Patients With R/R MM: 2-Yr Update
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
GRIFFIN Update: Dara-R Maintenance
GRIFFIN 2-Yr Maintenance Phase Update: Dara + VRd With Dara-R Maintenance vs VRd With R Maintenance for ASCT-Eligible Patients With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

View Activity
Venetoclax/Dara/Dex in R/R MM
Preliminary Phase I/II Results of Venetoclax/Dara/Dex vs Bortezomib/Dara/Dex in t(11;14) Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
MCARH109 CAR T-Cell Tx in R/R MM
MCARH109, a GPCRC5D-Targeted CAR T-Cell Therapy, in Relapsed/Refractory MM: A Phase I First-in-Class Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

View Activity
Final BELLINI Analysis: Venetoclax + Vd
Final Survival Analysis of BELLINI: Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
MajesTEC-1: Teclistamab in R/R MM
Updated Results From Phase I/II MajesTEC-1 Study: Teclistamab, a BCMA x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
ABBV-383 in R/R MM
BCMA x CD3 Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma: Update of a Phase I First-in-Human Study
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity

Activities

Hematology 2021: Myeloma
Key Studies in Multiple Myeloma: Independent Conference Coverage of ASH 2021
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 12, 2022

Expires: May 11, 2023

10 Capsule Summary Slidesets

Activities

Mitapivat for SCD
Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
SOLACE-kids
SOLACE-kids: Phase II Study of Crizanlizumab in Adolescents With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

View Activity
Iptacopan for PNH
Phase II Study of Iptacopan Monotherapy for Paroxysmal Nocturnal Hemoglobinuria: A 12-Mo Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
AREG: Monitoring in aGVHD
Amphiregulin as a Monitoring Biomarker for Patients With Acute GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

View Activity
uhCG/EGF for aGVHD
Phase II Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-threatening Acute GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
Axatilimab in cGVHD
Phase I/II Study of Anti‒CSF-1R Antibody Axatilimab in Heavily Pretreated Chronic Graft-vs-Host Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

View Activity
Abatacept for GVHD
Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
ATLAS-INH: Fitusiran for Hemophilia A/B
ATLAS-INH: Phase III Trial of Fitusiran Prophylaxis in Patients With Hemophilia A or B With Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity
Etavopivat in SCD
Exploratory Analyses From a Phase I Study of Etavopivat in Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
ATLAS-A/B
ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity

Activities

Hematology 2021: Nonmalignant
Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2021
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 01, 2022

Expires: February 28, 2023

11 Capsule Summary Slidesets

Activities

Ven + Aza in Poor-Risk AML
Pooled Analysis of Impact of TP53 Mutations on Efficacy of Venetoclax + Azacitidine in Patients With AML and Poor-Risk Cytogenetics
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

View Activity
ASCEMBL 48-week update
ASCEMBL: 48-Wk Update of Results From the Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
CPX-351 or HMA + Ven in AML
CPX-351 and HMA + Venetoclax as Frontline Therapy in AML: A Retrospective Comparative Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
Venetoclax/Decitabine in Adverse-Risk AML
Venetoclax/Decitabine for Young Adults With Newly Diagnosed ELN Adverse-Risk AML: Phase II Trial Interim Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

View Activity
GMALL 08/2013
GMALL 08/2013: First Results From the Risk-Adapted, MRD-Stratified Trial in Adults With Newly Diagnosed ALL/LBL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

View Activity
QUIZ/VEN/DAC in <i>FLT3</i>-Mutated AML
Evaluation of Quizartinib With Venetoclax and Decitabine Therapy in Patients With Newly Diagnosed or R/R FLT3-Mutated AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

View Activity
Aza/Ven/Magrolimab in AML
Combination Therapy With Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity
Low-Dose Dasatinib in CP-CML
Low-Dose Dasatinib vs Standard-Dose Dasatinib in Newly Diagnosed CP-CML: A Propensity Score Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity
Gilteritinib + Venetoclax in R/R AML
Phase Ib Study of Gilteritinib Combined With Venetoclax for R/R Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

View Activity
AGILE: Ivosidenib/AZA in AML
AGILE: Phase III Trial of Ivosidenib + Azacitidine vs Placebo + Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

View Activity
LACEWING
LACEWING: Phase III Study of Gilteritinib + Azacitidine vs Azacitidine for Patients With Newly Diagnosed FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

View Activity

Activities

Hematology 2021 Leukemias
Key Studies in Leukemias: Independent Conference Coverage of ASH 2021
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 06, 2022

Expires: April 05, 2023

Faculty

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

cover img faculity

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

cover img faculity

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

cover img faculity

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

cover img faculity

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.